Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension
Barst, Robyn J × Oudiz, Ronald J Beardsworth, Anthony Brundage, Bruce H Simonneau, Gerald Ghofrani, Hossein A Sundin, David P Galiè, Nazzareno Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group #
Journal of Heart and Lung Transplantation vol:30 issue:6 pages:632-43
Tadalafil 40 mg orally once daily, was shown to be well-tolerated and efficacious for pulmonary arterial hypertension in a 16-week, double-blind, placebo (PBO)-controlled trial. Inclusion criteria included the option for background bosentan. Analyses of tadalafil in treatment-naive patients and as add-on to bosentan were pre-specified. Objectives were to provide safety and efficacy data for both groups.